Yes, the four indications are excluded- and given that it is what Neuren wants to target it should have zero effect re valuations. Also, if Neuren wanted to go after another indication, I don't think it would be retrospective ie Acadia would surely have to have had commenced planning/trials at least?
Ann: Q2 2023 quarterly activity and cash flow report, page-11
-
- There are more pages in this discussion • 63 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.21 |
Change
-1.060(4.98%) |
Mkt cap ! $2.583B | |||
| Open | High | Low | Value | Volume |
| $20.98 | $21.06 | $20.14 | $6.308M | 308.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3926 | $20.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.21 | 388 | 1 |
View Market Depth
| Last trade - 16.10pm 01/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |